← 產業報告目錄
Nasal Vaccines Market Size, Share & Trends Analysis Report By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, and Conjugate Vaccines), By Application (Influenza, COVID-19), By Region, And By Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-19頁數 180報告編號 INSIGHTACE-dcf5cfedd1
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
In 2024, the Nasal Vaccines Market worldwide was assessed at USD 466.2 Million. Analysts project it will surge to USD 935.2 Million by 2034, at a CAGR of 8.6% spanning 2025 to 2034.
Nasal Vaccines encompasses a non-invasive substitute for conventional injection-based medication, offering a new and efficient method of protection against a range of infectious illnesses. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Several factors contribute to this trajectory, including heightened need next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, supported by rapid industrialization and expanding end-user bases.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Nasal Vaccines Market Snapshot
Chapter 4. Global Nasal Vaccines Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Nasal Vaccines Market Industry Trends
4.10. Global Nasal Vaccines Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Nasal Vaccines Market Segmentation 1: By Vaccine Type, Estimates & Trend Analysis
5.1. Market Share by Vaccine Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Vaccine Type:
5.2.1. Live Attenuated Vaccines
5.2.2. Inactivated Vaccines
5.2.3. Subunit
5.2.4. Recombinant and Conjugate Vaccines
5.2.5. Others
Chapter 6. Nasal Vaccines Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Influenza
6.2.2. COVID-19
6.2.3. Others
Chapter 7. Nasal Vaccines Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. Global Nasal Vaccines Market, Regional Snapshot 2024 & 2034
7.2. North America
7.2.1. North America Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.2.1.1. US
7.2.1.2. Canada
7.2.2. North America Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
7.2.3. North America Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
7.3. Europe
7.3.1. Europe Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.3.1.1. Germany
7.3.1.2. U.K.
7.3.1.3. France
7.3.1.4. Italy
7.3.1.5. Spain
7.3.1.6. Rest of Europe
7.3.2. Europe Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
7.3.3. Europe Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
7.4. Asia Pacific
7.4.1. Asia Pacific Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.4.1.1. India
7.4.1.2. China
7.4.1.3. Japan
7.4.1.4. Australia
7.4.1.5. South Korea
7.4.1.6. Southeast Asia
7.4.1.7. Rest of Asia Pacific
7.4.2. Asia Pacific Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
7.4.3. Asia Pacific Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
7.5. Latin America
7.5.1. Latin America Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
7.5.1.1. Brazil
7.5.1.2. Mexico
7.5.1.3. Rest of Latin America
7.5.2. Latin America Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
7.5.3. Latin America Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
7.6. Middle East & Africa
7.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
7.6.1.1. GCC Countries
7.6.1.2. South Africa
7.6.1.3. Rest of Middle East and Africa
7.6.2. Middle East & Africa Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Vaccine Type, 2021-2034
7.6.3. Middle East & Africa Nasal Vaccines Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Vaxart, Inc.
8.2.1.1. Business Overview
8.2.1.2. Key Service/Service Overview
8.2.1.3. Financial Performance
8.2.1.4. Geographical Presence
8.2.1.5. Recent Developments with Business Strategy
8.2.2. FluGen Inc.
8.2.3. Altimmune, Inc.
8.2.4. Sinovac Biotech Ltd.
8.2.5. Sanofi Pasteur SA
8.2.6. Pfizer Inc.
8.2.7. GlaxoSmithKline plc
8.2.8. Johnson & Johnson
8.2.9. Ennaid Therapeutics, LLC
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們